跳至主要内容
临床试验/NCT06772025
NCT06772025招募中不适用

Methodology Study in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass to Investigate Mechanisms Involved in Cardiac Surgery-associated Acute Kidney Injury.

Bayer8 个研究点 分布在 2 个国家目标入组 200 人开始时间: 2025年2月3日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
8
主要终点
Number of participants with CSA-AKI until Day 3 post-surgery

研究概览

简要总结

Researchers are looking for a better way to treat and prevent cardiac surgery-associated acute kidney injury (CSA-AKI) in people who undergo heart surgeries.

CSA-AKI is a common complication in people undergoing heart surgeries, where the kidneys stop working properly. CSA-AKI risk factors include older age and alongside diseases such as kidney disease and diabetes. Longer time with heart-lung machine during heart surgeries also increases the occurrence of CSA-AKI.

In this study, researchers want to better understand how CSA-AKI develops (also known as the mechanisms involved in the development of CSA-AKI) in people under heart surgeries, the presence of certain biomarkers in the body, especially with a focus on the early hours and days after the surgery. (A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.) These biomarkers will be compared in participants who develop CSA-AKI within a week after heart surgery with the participants who do not develop CSA-AKI. The relationship with biomarkers will be determined by examining participants' blood and urine samples before and after surgery.

This may help researchers better understand CSA-AKI, identify potential treatment targets and develop possible treatments to prevent CSA-AKI.

Participants in this study will be people who have heart surgery already scheduled by their own doctors and have a risk of developing CSA-AKI. Participants will not receive any treatment as part of this study. They will undergo the heart surgery and related medical processes as per their normal medical treatment and management.

Each participant will be in the study for up to 2 months. During the study, the doctors and their study team will:

  • collect participants' blood and urine samples before and after surgery
  • assess participants' medical records and test reports during hospitalization
  • monitor overall health of the participants throughout the study

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participant must be at least 18 years of age at the time of signing the informed consent form (ICF).
  • Participants who are scheduled for hospital admission for any of the following cardiovascular surgery interventions, alone or in combination, involving cardiopulmonary bypass (CPB):
  • Aortic, mitral, or tricuspid valve surgery (repair or replacement)
  • Aortic surgery
  • ≥3 coronary artery bypass grafts
  • Participant with: chronic kidney disease (CKD): 30 ≤ estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m^2

排除标准

  • Emergency surgery situation
  • Anemia - hemoglobin <10 g/dL
  • Clinical signs of systemic infection or other infection requiring anti-infective treatment (viral, bacterial, fungal, parasitic; single-dose prophylaxis allowed)
  • Systemic immunosuppressive or anti-inflammatory treatment including corticosteroids >10 mg prednisolone equivalent/day
  • Any anti-cancer treatment within 3 months (e.g. immunotherapy, chemotherapy, radiotherapy)
  • Major surgery within 2 months
  • AKI within the last month
  • Prior renal transplants or RRT
  • Planned use of contrast media within 5 days prior to surgery or during surgery
  • Patient included in an interventional clinical trial involving a pharmacological intervention
  • Any reason that would make participation unadvisable, at the discretion of the investigator.
  • Autoimmune disorders such as anti-glomerular basement membrane (anti-GBM) diseases, systemic lupus erythematosus, chronic rheumatic heart diseases, acute rheumatic heart pericarditis, endocarditis, myocarditis, rheumatic mitral valve diseases, rheumatic aortic valve diseases

研究组 & 干预措施

Cardiac surgery

Experimental

Patients scheduled for cardiac surgery with cardiopulmonary bypass will be managed according to local standard medical care. Blood and urine will be obtained pre-surgery and post-surgery for analysis.

干预措施: No investigational study intervention (Other)

结局指标

主要结局

Number of participants with CSA-AKI until Day 3 post-surgery

时间窗: Up to 3 days post surgery

CSA-AKI: cardiac surgery-associated acute kidney injury

次要结局

  • Observed values of pre-defined biomarkers overall and by CSA-AKI outcome(Up to 7 days post surgery)
  • Change from baseline of pre-defined biomarkers overall and by CSA-AKI outcome(Up to 7 days post surgery)
  • Ratio to baseline of pre-defined biomarkers overall and by CSA-AKI outcome(Up to 7 days post surgery)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验